Advertisement
UK markets close in 7 hours 33 minutes

  • FTSE 100

    8,123.10
    +44.24 (+0.55%)
     

  • FTSE 250

    19,748.61
    +146.63 (+0.75%)
     

  • AIM

    755.59
    +2.47 (+0.33%)
     

  • GBP/EUR

    1.1656
    -0.0000 (-0.00%)
     

  • GBP/USD

    1.2511
    -0.0000 (-0.00%)
     

  • Bitcoin GBP

    51,394.20
    +204.25 (+0.40%)
     

  • CMC Crypto 200

    1,387.53
    -9.01 (-0.64%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.03
    +0.46 (+0.55%)
     

  • GOLD FUTURES

    2,357.20
    +14.70 (+0.63%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,660.93
    +376.39 (+2.18%)
     

  • DAX

    18,015.32
    +98.04 (+0.55%)
     

  • CAC 40

    8,037.66
    +21.01 (+0.26%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Fluidigm Unveils High-Throughput Integrated Fluidic Circuit

Zacks Equity Research
Updated

South San Francisco, CA-based Fluidigm Corporation FLDM, a leading player in the analysis of single cells and industrial application of genomics, recently unveiled a new high-throughput integrated fluidic circuit (HT IFC) to separate single cells during mRNA sequencing analysis.

Over the past six months, Fluidigm has traded below the Zacks categorized Medical Instruments sub-industry. The stock currently represents a negative return of 23.08%, much wider than the sub-industry’s decline of 2.6%. Additionally, Fluidigm lost 6.8% to close at $7.40 yesterday, following the dismal trends. Year to date, the company represented a loss of 31.5% while the S&P 500 rose 8.9%.

On the positive side, Fluidigm has compelling fundamentals in terms of revenues, multiplying at a CAGR of 27.3% over the last three years. Additionally, a long-term earnings growth rate of 25% instills investor confidence. Average volume of shares traded over the last three months was remarkable at approximately 259.2k. Currently, the stock has a market cap of $232.36 million.

ADVERTISEMENT

Getting back to the development, HT IFC leverages on the company’s flagship Fluidigm C1 system, a leading automated solution for single-cell genomics. The introduction of the new medium-cell HT IFC paves way for greater single-cell capture and better workflow performance.

Per management, the latest development will provide researchers a strong platform to discover the wide range of cell populations (at single-cell resolution) and understand the role of rare cells in our lives.

Of the recent developments at the company, the distribution agreement with GenomOncology is worth mentioning. Per the terms of the deal, both the companies would co-market the ‘GO Clinical Workbench’, a knowledge-based software that provides decision support for oncology research programs.

FLUIDIGM CORP Price

 

FLUIDIGM CORP Price | FLUIDIGM CORP Quote

For the coming quarters, Fluidigm is expected to develop small-cell HT IFC to provide high-throughput capabilities for neuronal and immune cell populations.

Our Take

Considering the opportunities for single cell analysis in the global markets, the recent development indicates possibilities of revival for the stock over the long term. On that note, a research report by Markets And Markets reveals that niche markets are expected to reach a worth of 3.35 billion by 2021, multiplying at a CAGR of 18.2%.

Zacks Rank & Key Picks

Currently, Fluidigm has a Zacks Rank #3 (Hold).

Better-ranked stocks in the broader medical sector include Addus HomeCare Corporation ADUS, LHC Group, Inc. LHCG and IDEXX Laboratories, Inc. IDXX. Addus HomeCare and IDEXX Laboratories sport a Zacks Rank #1 (Strong Buy). Meanwhile, LHC Group carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Addus HomeCare has a long-term expected earnings growth rate of approximately 15%. Notably, the stock represents an impressive one-year return of 50%.

LHC Group has a long-term expected earnings growth rate of 15%. The company has returned almost 17.6% in the last three months.

IDEXX Laboratories has an expected earnings growth of almost 15%. The company posted a promising year-to-date return of almost 64%.

The Best Place to Start Your Stock Search

Today, you are invited to download the full list of 220 Zacks Rank #1 ""Strong Buy"" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 ""Strong Sells"" and other private research. See these stocks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
IDEXX LABS INC (IDXX): Free Stock Analysis Report
 
FLUIDIGM CORP (FLDM): Free Stock Analysis Report
 
LHC GROUP LLC (LHCG): Free Stock Analysis Report
 
ADDUS HOMECARE (ADUS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research